A smartphone-guided secondary prevention digital health application reduces systolic blood pressure in patients with chronic coronary syndrome and insufficient blood pressure control.

IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Frontiers in Cardiovascular Medicine Pub Date : 2025-02-10 eCollection Date: 2025-01-01 DOI:10.3389/fcvm.2025.1515598
Philip Düsing, Stephan H Schirmer, Sebastian Schäfer, Alexander Krogmann, Jan-Malte Sinning, Nikos Werner, Florian Bönner, Alexander Sedaghat, Cornelius Müller, Irina Eckardt, Georg Nickenig, Andreas Zietzer
{"title":"A smartphone-guided secondary prevention digital health application reduces systolic blood pressure in patients with chronic coronary syndrome and insufficient blood pressure control.","authors":"Philip Düsing, Stephan H Schirmer, Sebastian Schäfer, Alexander Krogmann, Jan-Malte Sinning, Nikos Werner, Florian Bönner, Alexander Sedaghat, Cornelius Müller, Irina Eckardt, Georg Nickenig, Andreas Zietzer","doi":"10.3389/fcvm.2025.1515598","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic coronary syndrome (CCS) leads to high morbidity and mortality despite therapeutic advances in recent decades. Several modifiable risk factors, including increased blood pressure (BP), significantly contribute to cardiovascular risk in CCS. Therefore, optimal secondary prevention includes managing BP through lifestyle changes and pharmacological therapy. The CHANGE study aimed to provide evidence for optimizing secondary prevention in CCS patients using a smartphone application.</p><p><strong>Methods: </strong>The CHANGE-Study is a prospective, randomized, controlled trial performed in 9 centers in Germany. Patients with CCS were randomly allocated to either a control or an intervention group. The intervention group received the \"Vantis | KHK und Herzinfarkt\" digital health application and standard care. The control group received standard care alone. From the original cohort, subgroups of patients with systolic BP ≥140 mmHg (<i>n</i> = 44), ≥130 mmHg (<i>n</i> = 89) and diastolic BP ≥90 mmHg (<i>n</i> = 28) were analyzed for BP reduction after 12 weeks.</p><p><strong>Results: </strong>In patients with systolic BP ≥140 mmHg, the intervention group showed a reduction in systolic BP by 15.5 mmHg (± 16.7 mmHg, <i>p</i> = 0.0001), which was greater compared to the control group (6.0 ± 13.0 mmHg, <i>p</i> = 0.058). This observation was consistent in patients with systolic BP ≥130 mmHg at baseline. No significant differences between both groups were observed in diastolic BP reduction in patients with diastolic BP ≥90 mmHg.</p><p><strong>Conclusion: </strong>The CHANGE study documents that a smartphone-guided digital health application positively affects systolic BP in CCS patients. This study underlines the potential of digital interventions in cardiology to improve secondary prevention.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1515598"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11847794/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1515598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic coronary syndrome (CCS) leads to high morbidity and mortality despite therapeutic advances in recent decades. Several modifiable risk factors, including increased blood pressure (BP), significantly contribute to cardiovascular risk in CCS. Therefore, optimal secondary prevention includes managing BP through lifestyle changes and pharmacological therapy. The CHANGE study aimed to provide evidence for optimizing secondary prevention in CCS patients using a smartphone application.

Methods: The CHANGE-Study is a prospective, randomized, controlled trial performed in 9 centers in Germany. Patients with CCS were randomly allocated to either a control or an intervention group. The intervention group received the "Vantis | KHK und Herzinfarkt" digital health application and standard care. The control group received standard care alone. From the original cohort, subgroups of patients with systolic BP ≥140 mmHg (n = 44), ≥130 mmHg (n = 89) and diastolic BP ≥90 mmHg (n = 28) were analyzed for BP reduction after 12 weeks.

Results: In patients with systolic BP ≥140 mmHg, the intervention group showed a reduction in systolic BP by 15.5 mmHg (± 16.7 mmHg, p = 0.0001), which was greater compared to the control group (6.0 ± 13.0 mmHg, p = 0.058). This observation was consistent in patients with systolic BP ≥130 mmHg at baseline. No significant differences between both groups were observed in diastolic BP reduction in patients with diastolic BP ≥90 mmHg.

Conclusion: The CHANGE study documents that a smartphone-guided digital health application positively affects systolic BP in CCS patients. This study underlines the potential of digital interventions in cardiology to improve secondary prevention.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
智能手机引导的二级预防数字健康应用程序可降低慢性冠状动脉综合征和血压控制不足患者的收缩压。
背景:慢性冠状动脉综合征(CCS)的发病率和死亡率很高,尽管近几十年来治疗取得了进展。几个可改变的危险因素,包括血压升高,显著增加了CCS患者的心血管风险。因此,最佳的二级预防包括通过改变生活方式和药物治疗来控制BP。CHANGE研究旨在为使用智能手机应用程序优化CCS患者的二级预防提供证据。方法:CHANGE-Study是一项在德国9个中心进行的前瞻性、随机、对照试验。CCS患者被随机分配到对照组或干预组。干预组接受“Vantis | KHK und Herzinfarkt”数字健康应用和标准护理。对照组仅接受标准治疗。从原始队列中,对收缩压≥140 mmHg (n = 44)、≥130 mmHg (n = 89)和舒张压≥90 mmHg (n = 28)患者的亚组进行了12周后血压降低的分析。结果:在收缩压≥140 mmHg的患者中,干预组收缩压降低15.5 mmHg(±16.7 mmHg, p = 0.0001),优于对照组(6.0±13.0 mmHg, p = 0.058)。这一观察结果在基线收缩压≥130 mmHg的患者中是一致的。舒张压≥90mmhg患者的舒张压降低在两组间无显著差异。结论:CHANGE研究证明,智能手机引导的数字健康应用程序对CCS患者的收缩压有积极影响。这项研究强调了数字干预在心脏病学中改善二级预防的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.80
自引率
11.10%
发文量
3529
审稿时长
14 weeks
期刊介绍: Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.
期刊最新文献
Kindlins in the cardiovascular system: from development to pathogenesis. Pathogenic role of mitochondrial DNA mutations in heart failure: clinical features, mechanisms, and therapeutic prospects. Impact of renal denervation on circadian variations of blood pressure and clock gene expression in spontaneously hypertensive rats. Protective effects of beta-blockers against anthracycline- and trastuzumab-related cardiotoxicity: a systematic review based on conventional and Bayesian network meta-analysis. Rapid bedside multimodal ultrasound screening for acute type A aortic dissection: a perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1